U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07865832) titled 'A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma' on Sept. 30.
Brief Summary: Clear cell renal cell carcinoma is the most common type of kidney cancer. Although new treatments such as immune checkpoint inhibitors and targeted therapies have improved outcomes for many patients, some patients with advanced disease may still experience disease progression and require new treatment approaches. This study evaluates the safety, feasibility, and preliminary effectiveness of a novel cell therapy called CA9-targeted chimeric antigen receptor macrophage (CAR-M) therapy in patients with unresectable or ...